Dr. Philip A. Dy, MD

Dr. Dy practices at Cancer Care Specialists of Central Illinois, S.C. in Decatur, Illinois.

Dr. Dy's NPI, 1710076567, was assigned on October 12, 2006. Dr. Dy holds Illinois license 036097243.

Dr. Dy's primary practice is Cancer Care Specialists of Central Illinois, S.C., at 210 W McKinley Ave, Decatur, IL 62526 in Macon County. The practice phone is (217) 876-6600.

Dr. Dy's primary practice is Cancer Care Specialists of Central Illinois, S.C. in Decatur, Illinois. Dr. Dy is also affiliated with Sarah Bush Lincoln Health Center. The medical group on file is Cancer Care Specialists of IL. Dmand AI also links Dr. Dy to 4 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dy practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dy's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dy is licensed in Illinois.

CMS data shows 540,971 Medicare services from Dr. Dy across 103 procedure codes in 2024, for 1,147 Medicare patients. Medicare paid $6,538,731 for them. Every service was in an office.

CMS counts 1,147 Medicare patients who saw Dr. Dy in 2024. The largest group is 65 to 74, with 490 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dy's median patient age at 73, with 61% women.

In 2024, Dr. Dy wrote 3,993 Medicare Part D claims for 515 patients. 82% of them were for generic drugs. CMS names the drug for 3,653 of them, across 62 drugs with 11 or more claims each, at $6,943,427 in total drug cost. In 2023, CMS named 3,071 claims across 61 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dy for performance year 2024, reported as part of a group. Dr. Dy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dy as offering telehealth.

Dmand AI links 6 papers to Dr. Dy, published from 2011 to 2020. 2016 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols. Dr. Dy's most frequent co-authors are Gabriel N. Hortobagyi, MD, Anne F. Schott, MD and Ranjana Advani, MD.

CMS Open Payments shows 581 general payments to Dr. Dy from 59 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 58% of the total. TESARO, Inc. paid the most, $3,497.